Healthcare industry leader, Syngene International Limited, is demonstrating not just robust growth but also strategic advancement. Achieving a 26% YoY increase in both revenues and profit after tax, Syngene’s financial success is paving the way for further business expansion.
One such move includes the acquisition of a biologics manufacturing facility from Stelis Biopharma Ltd. Adding 20,000 liters of installed biologics capacity to its portfolio, Syngene is set to further solidify its presence in the biologics contract development and manufacturing sector.
Simultaneously, the company has achieved significant validation with the FDA’s approval of its Mangalore-based API manufacturing facility. This nod from the FDA underscores the robust quality standards that Syngene upholds in its operations.
The company’s dedication to research is clear as it acquires additional land in Hyderabad, paving the way for further growth in its Research Services division.
